A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases

Objective No efficient medical treatment is available for severe acute hepatitis (SAH) except N-acetylcysteine for acetaminophen-induced acute liver failure. The human C-type lectin Reg3α, referred to as ALF-5755, improved survival in an animal model of acute liver failure and was well tolerated in a phase 1 trial in humans. We performed a phase 2a trial of ALF5755 in non-acetaminophen induced SAH. Design double-blind, randomized, placebo-controlled study. The primary end-point was the improvement in the coagulation protein synthesis assessed by the change of Prothrombin (PR) during the 72 hours following treatment initiation calculated as PRH0 minus PRH72 divided by 72 (PR slope H0H72). Intention to treat (ITT) and per-protocol (PP) analysis of the entire group and the Hepatitis B virus (HBV)/AIH (auto-immune hepatitis) sub-group were done separately. Results 57 patients were included. Twenty-eight received ALF-5755, 29 the placebo. Etiologies were: Hepatitis A (n = 10), HBV (n = 13), AIH (n = 9), drug-induced (n = 8), other (n = 17). On the whole group, nor the PR slope H0H72 (0.18±0.31 vs 0.25±0.32), nor the transplant-free survival rate at day 21 (75 vs 86%) differed between groups. Conversely, in the HBV-AIH subgroup, in which ALF was more severe, PR slope H0-H72 was higher in the ALF-5755 arm, the difference being significant in PP analysis (0.048±0.066 vs -0.040±0.099, p = 0.04); the median length of hospitalization was lower in the ALF-5755 group (8 vs 14 days, p = 0.02). Conclusion ALF-5755 was not efficient in a ITT analysis performed on the whole sample; however it led to a significant, although moderate, clinical benefit in a PP analysis of the sub-group of patients with HBV or AIH related SAH. As HBV is the major cause of SAH in Asia and Africa and AIH a growing cause, this study emphasizes the need to pursuit the evaluation of this novel medical treatment of SAH. Trial Registration ClinicalTrials.gov NCT01318525

[1]  D. Samuel,et al.  The Reg3α (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure , 2015, PloS one.

[2]  W. Kim,et al.  Toward an improved definition of acute-on-chronic liver failure. , 2014, Gastroenterology.

[3]  Gui‐qing Li,et al.  C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression , 2014, Hepatology.

[4]  M. Mendizabal,et al.  Changing etiologies and outcomes of acute liver failure: Perspectives from 6 transplant centers in Argentina , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  J. O'grady.  Timing and benefit of liver transplantation in acute liver failure. , 2014, Journal of hepatology.

[6]  S. Bass,et al.  Intravenous acetylcysteine for indications other than acetaminophen overdose. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  M. Mcphail,et al.  Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. , 2013, Journal of hepatology.

[8]  P. Kamath,et al.  Acute-on chronic liver failure. , 2012, Journal of hepatology.

[9]  M. Yuen,et al.  Acute‐on‐chronic liver failure in chronic hepatitis B , 2012, Journal of gastroenterology and hepatology.

[10]  D. Samuel,et al.  Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases , 2011, Gut.

[11]  D. Samuel,et al.  Human hepatocarcinoma‐intestine‐pancreas/pancreatitis‐associated protein cures fas‐induced acute liver failure in mice by attenuating free‐radical damage in injured livers , 2011, Hepatology.

[12]  William M. Lee,et al.  Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. , 2009, Gastroenterology.

[13]  William M. Lee,et al.  Acute liver failure: Summary of a workshop , 2007, Hepatology.

[14]  D. Samuel,et al.  Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  S. Pervaiz,et al.  TNF receptor superfamily‐induced cell death: redox‐dependent execution , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  William M. Lee,et al.  AASLD Position Paper: The Management of Acute Liver Failure: Update 2011 , 2011 .

[17]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[18]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[19]  Roger Williams,et al.  Acute liver failure: redefining the syndromes , 1993, The Lancet.

[20]  A. Forbes,et al.  Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. , 1991, BMJ.

[21]  G. Alexander,et al.  Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. , 1990, BMJ.

[22]  J. Bernuau,et al.  Fulminant and Subfulminant Liver Failure: Definitions and Causes , 1986, Seminars in liver disease.

[23]  Pamela L. Smithburger,et al.  Use of acetylcysteine for non-acetaminophen-induced acute liver failure. , 2013, Annals of hepatology.

[24]  E. Elinav,et al.  The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy. , 2005, Journal of hepatology.

[25]  K. Böker,et al.  Akutes Leberversagen , 2001, Der Internist.